|
|
| (3 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Olmesartan]] |
| | IUPAC_name = (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[ [4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
| |
| | image = olmesartan.png
| |
| | CAS_number = 144689-63-4
| |
| | ATC_prefix = C09
| |
| | ATC_suffix = CA08
| |
| | ATC_supplemental =
| |
| | PubChem = 130881
| |
| | DrugBank = APRD00223
| |
| | C=29 | H=30 | N=6 | O=6
| |
| | molecular_weight = 558.585 g/mol
| |
| | bioavailability = Rapid and complete absorption
| |
| | protein_bound =
| |
| | metabolism = Hepatic (cannot be removed by hemodialysis)
| |
| | elimination_half-life = 13 hours
| |
| | pregnancy_category = C (D if used in second or third trimester)
| |
| | legal_status = Rx-only
| |
| | routes_of_administration = Oral
| |
| | excretion = Primarily fecal, 35%-50% in urine
| |
| }}
| |
| {{CMG}}
| |
| __NOTOC__
| |
| {{Editor Join}}
| |
| | |
| ==[[Olmesartan (patient information)|For patient information, click here]]==
| |
| | |
| ==Overview==
| |
| '''Olmesartan''' (Benicar®,Olmetec®) belongs to the class of medicines called [[angiotensin II receptor antagonist]]s to treat [[hypertension|high blood pressure]]. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the [[United States]] by Daiichi Sankyo, Inc. and [[Forest Laboratories]]. Olmesartan works by blocking the binding of [[Angiotensin|angiotension II]] to the AT<sub>1</sub> receptors in vascular muscle; it is therefore independent of angiotension II synthesis pathways, unlike [[ACE inhibitor]]s. By blocking binding rather than synthesis of angiotension II, olmesartan inhibits the negative regulatory feedback on [[renin]] secretion. As a result of this blockage, olmesartan restricts [[vasoconstriction]] and the secretion of [[aldosterone]]. This lowers blood pressure by producing [[vasodilation]], and decreasing peripheral resistance.
| |
| | |
| ==Administration==
| |
| Olmesartan is available in 5, 20, and 40 mg tablets. A normal dose for an adult (including the elderly and mild renal or hepatic impairment) is 20 mg/day in one dosage. This may be increased after two weeks to 40 mg/day if further blood pressure reduction is needed.
| |
| | |
| ==Side effects==
| |
| Side effects include:
| |
| *[[Dizziness]]
| |
| *[[Headache]]
| |
| *[[Diarrhea]]
| |
| *[[Upper respiratory tract infection]]
| |
| | |
| ==References==
| |
| Hodgson, Barbara B., and Kizior, Robert J. ''Saunders Nursing Drug Handbook 2006''. St. Louis, MO: Elsevier, Saunders, 2006.
| |
| | |
| ==External links==
| |
| *[http://www.frx.com/products/benicar.aspx Forest Laboratories Benicar page]
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Imidazoles]]
| |
| [[Category:Drugs]]
| |
| | |
| [[de:Olmesartan]]
| |
| [[hu:Olmesartan]]
| |
| [[pt:Olmesartan]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |